Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $20.00.

Several equities analysts recently commented on ANRO shares. Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $29.00 to $4.00 in a report on Wednesday, October 23rd. Robert W. Baird decreased their target price on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Stifel Nicolaus cut their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. purchased a new position in shares of Alto Neuroscience during the first quarter worth about $8,233,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Alto Neuroscience in the 1st quarter valued at approximately $9,788,000. AWM Investment Company Inc. acquired a new position in shares of Alto Neuroscience in the first quarter valued at approximately $4,592,000. Zimmer Partners LP purchased a new stake in shares of Alto Neuroscience during the first quarter worth approximately $1,151,000. Finally, Artal Group S.A. acquired a new stake in shares of Alto Neuroscience during the first quarter worth $5,372,000.

Alto Neuroscience Trading Up 5.4 %

Shares of NYSE ANRO opened at $4.31 on Monday. The stock’s 50-day moving average is $8.77 and its two-hundred day moving average is $10.92. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. Alto Neuroscience has a 1-year low of $3.61 and a 1-year high of $24.00.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. Analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.